Comparative effectiveness of torsemide vs furosemide in the management of heart failure patients: Win-ratio reanalysis of the TRANSFORM-HF trial.
Am Heart JJul 8, 2026 (epub)
Guangyu Tong, Yukang Zeng, Stephen J Greene et al.
✦ AI-curated · Sources linked
In 30 seconds
This study reanalyzed the TRANSFORM-HF trial, a multicenter randomized trial involving 2,859 heart failure patients, comparing torsemide and furosemide. The primary outcome, assessed using a hierarchical win-ratio framework, showed no significant difference in the composite outcome of all-cause mortality, rehospitalizations, and health status at 12 months (adjusted WR 1.07; P = .13).
Key findings
- The adjusted win-ratio for torsemide vs furosemide was 1.07 (95% CI, 0.98-1.16; P = .13) at 12 months.
- A 30-month analysis yielded a similar adjusted win-ratio of 1.06 (95% CI, 0.98-1.16; P = .14).
- No significant differences were found in hospitalization rates or KCCQ-CSS scores between the two diuretics.
Why it matters
Understanding the comparative effectiveness of loop diuretics like torsemide and furosemide is crucial for optimizing heart failure management. This study provides insights into their similar outcomes, which may influence treatment decisions.